This article was originally published in The Gray Sheet
Executive SummaryBoard of directors authorizes repurchase up to 12 mil. shares of common stock "for use in employee stock option, stock repurchase and other benefit plans, and other authorized corporate purposes." The repurchase plan extends a November 1990 board authorization for the purchase of up to 13.5 mil. shares. Baxter has already bought back 12.5 mil. shares under the 1990 and prior grants of authority.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.